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Changes in mitochondrial DNA (mtDNA) content in cancers have been reported with controversial results, probably due to small
sample size and variable pathological conditions. In this study, mtDNA content in 302 breast tumor/surrounding normal tissue
pairs were evaluated and correlated with the clinico-pathological characteristics of tumors. Overall, mtDNA content in tumor
tissues is signiﬁcantly lower than that in the surrounding normal tissues, P<0.00001. MtDNA content in tumor tissues decreased
with increasing tumor size. However, when the tumor is very large (>50cm3), mtDNA content started to increase. Similarly,
mtDNA content decreased from grades 0 and I to grade II tumors, but increased from grade II to grade III tumors. Tumors with
somatic mtDNA alterations in coding region have signiﬁcantly higher mtDNA content than tumors without somatic mtDNA
alterations (P<0.001). Tumors with somatic mtDNA alterations in the D-Loop region have signiﬁcantly lower mtDNA content
(P<0.001). Patients with both low and high mtDNA content in tumor tissue have signiﬁcantly higher hazard of death than
patients with median levels of mtDNA content. mtDNA content in tumor tissues change with tumor size, grade, and ER/PR status;
signiﬁcant deviation from the median level of mtDNA content is associated with poor survival.
1.Introduction
Mitochondria are the small power houses of the human cells.
They consume oxygen to generate about 80%∼90% of the
energy supply for the cell in the form of ATP and much of
the endogenous reactive oxygen (ROS) via oxidative phos-
phorylation (OXPHOS). Mitochondria also play an impor-
tant role in programmed cell death through the release of cy-
tochrome c from mitochondria to trigger a proteolytic cas-
cade involving caspases. Mitochondria have their own ge-
nome. Depending on the cell type, each cell contains hun-
dreds to thousands copies of mitochondrial DNA (mtDNA).
The mtDNA content is related to the energy demand of each
cell type. For example, each muscle cell contains several
thousands of copies of mtDNA molecules, while each skin
cell contains several hundreds of copies. Human mtDNA
encodes 13 protein subunits of the respiratory chain as well
as 2rRNAs and a set of 22tRNAs, essential for mitochondrial
protein synthesis [1].
About eighty years ago, Warburg observed an increased
capacity of aerobic glycolysis in cancers, it has been postu-
lated that cancer might be the result of altered mitochon-
drial function [2, 3]. Subsequent studies revealed that the
mitochondrial functions (OXPHOS) are downregulated in2 Journal of Oncology
many cancers [4]. Recently, alterations in mtDNA content
have been reported in a variety of cancers, but the results
are controversial. Kim et al. [5] reported that mitochondrial
DNA quantity increases with histopathological grade in
premalignant and malignant head and neck lesions. Using
quantitative real-time PCR analysis to study mtDNA con-
tents in 59 cases of paired invasive tumor and surrounding
nontumor breast tissues, Yu et al. showed that reduced
mitochondrialDNAcopynumberwascorrelatedwithtumor
progression and prognosis in Chinese breast cancer patients
[6]. In human hepatocellular carcinoma (HCC), the mtDNA
content was found to be signiﬁcantly reduced in female
HCC but not in male HCC [7]. Studies of primary epithelial
ovarian carcinomas revealed that mtDNA contents in tumor
cells were signiﬁcantly higher than those in normal ovarian
tissue. The average mtDNA content in pathologically low-
grade tumors was over twofold higher than that in high-
grade carcinomas [8]. These authors concluded that there
is an association of decreased mtDNA with ovarian cancer
progression [8]. mtDNA depletion was also reported to be
associated with tumor aggressiveness in renal cell carcinoma
[9] and with less-diﬀerentiated gastric carcinoma [10]. The
explanations for these controversial results could be tissue
speciﬁcity or stage- and class-speciﬁc changes of mtDNA
copy number [11]. It is also possible that the discrepancy is
due to small sample size of these studies.
In this report, we investigated the mtDNA content in 302
breast tumors and their corresponding surrounding patho-
logically normal tissues. We also correlated the mtDNA con-
tents with the clinicopathological features.
2.MaterialsandMethods
2.1. DNA Samples. Total DNA was isolated from 302 breast
tumors and their surrounding normal tissues using pro-
teinase K digestion, phenol-chloroform extraction, ethanol
precipitation method. The surrounding normal tissue was
deﬁned as pathologically and morphologically normal, with-
out evidence of hyperplasia. Alterations at molecular level
were not examined other than the studies presented in this
report. This study was carried out according to Institutional
Review Board (IRB) approved protocols. Informed consent
wasobtainedfromeachpatientwhosesampleswereincluded
in the study when the samples were collected.
2.2. Determination of mtDNA Content by Real-Time Quanti-
tative PCR. The real-time PCR reaction was performed in
duplicate for each mitochondrial and nuclear probe using
primers, mtF3212 and mtR3319 for mitochondrial tRNA-
Leu(UUR)geneandF589andR674forbeta2microglobulin
nuclear gene (B2M) as previously described [12]. The copy
number ratio of mtDNA to B2M gene (mtDNA/B2M) cal-
culated using delta Ct method was used as mtDNA content
[12].Thetumor/normalratio(T/Nratio)ofmtDNAcontent
indicates the ratio of the mtDNA content in tumor tissue to
the mtDNA content in the surrounding normal tissue from
the same patient. T/N ratio > 1 means the mtDNA content
increases in tumor tissue compared to the surrounding
normal tissue. T/N ratio < 1 means the mtDNA content
decreases in the tumor tissue compared to the surrounding
normal tissue.
2.3. Screening of Somatic mtDNA Changes in Tumors. For a
subset of 74 pairs of samples, somatic mtDNA alterations
in tumors were screened by temporal temperature gradient
gel electrophoresis (TTGE) as previously described [13–16].
The subset of samples analyzed for mtDNA alterations were
chosen randomly from and is similar in clinico-pathological
features (similar proportion of patients have the same fea-
tures in terms of the age group, tumor type, tumor size
group,pathologicalgrade,TNMstage;Fisher’sexactP values
are all greater than 0.5) to the entire sample set, so that
the subset of samples may represent the entire sample set.
The PCR products of DNA fragments from tumor and its
surrounding normal tissues were analyzed side by side. On
TTGE analysis, a single band shift represents a homoplasmic
DNA alteration, and a multiple-banding pattern represents a
heteroplasmic change.
2.4. Identiﬁcation of Somatic mtDNA Alterations by DNA
Sequencing. DNA fragments showing diﬀerences in TTGE
banding patterns between tumors and the surrounding nor-
maltissues were sequencedto identify theexact changes[13–
16] .T h em t D N As e q u e n c ed i ﬀerences between the tumor
and the surrounding normal tissue were scored as somatic
alterations.
2.5. Statistical Analysis. The mtDNA content or T/N ratio
among diﬀerent groups within a given variable (e.g., age,
size, and grade) was compared using nonparametric tests
(Mann-Whitney test or Kruskal-Wallis test). Fisher’s exact
test was used to correlate the change (increase or decrease)
in mtDNA content with the presence of somatic alterations
in coding or noncoding D-loop regions. Cox proportional-
hazards survival regression analysis was used to investigate
the relationship between the survival time, clinicopatholog-
ical variables, mtDNA content, and T/N ratio of mtDNA
content using both univariate and multivariate models. The
outcome was the overall survival, deﬁned from date of
tumor diagnosis to the death of any cause. Hazard ratios
were presented with their 95% conﬁdence intervals (95%
CI). All statistical tests were two sided. P values less than
0.05 are considered statistically signiﬁcant. All the tests were
performed using the SPSS 13.0 (SPSS Inc. Chicago, Illinois).
3. Results
3.1. Reduced mtDNA Content in the Majority of Tumor
Tissues. In a total of 302 tissue pairs, 9 pairs were excluded
fromstatisticalanalysisduetoreal-timePCRfailureforDNA
samples from either the tumor tissue or the surrounding
normal tissue. In the remaining 293 pairs, the mtDNA
content in tumor tissues (583 ± 511) is signiﬁcantly lower
than that in the surrounding normal tissues (688±389), P =
3.069e − 6. About 65% (191/293) of tumor tissues have re-
duced mtDNA content when compared to their surroundingJournal of Oncology 3
Table 1: Correlation of mtDNA content in breast cancer with clinicopathological features.
mtDNA content in tumor tissue T/N ratio of mtDNA content
n Mean ± SD P value∗ Mean ± SD P value∗
Age (years)
<40 56 592 ± 530 0.861 ± 0.561
40–49 103 588 ± 473 0.603 0.967 ± 0.7 0.817
50–59 77 574 ±515 0.956 ± 0.92
≥60 57 577 ± 402 0.956 ± 0.849
Tumor size (cm3) (versus C) (versus C)
A: ≤4.9 79 735 ± 412 4.06e −07 1.088 ± 0.636 1.84e −05
B: 5∼14.9 66 574 ± 354 0.004 1.000 ± 0.556 0.002
C: 15–49.9 75 372 ± 248 0.696 ± 0.459
D: ≥50 53 535 ± 385 0.306 0.818 ± 0.553 0.258
Grade
0∼I 18 669 ± 412 0.995 ± 0.681
II 125 506 ± 318 0.019 (versus0∼I) 0.791 ± 0.531 0.827 (versus 0∼I)
III 98 648 ± 432 0.383 (versus 0∼I)
0.006 (versusII) 1.128 ± 0.988 0.441 (versus 0∼I)
0.033 (versusII)
ER
Negative 107 502 ± 405 0.103 0.810 ± 0.612 0.047
Positive 157 573 ± 374 1.057 ± 1.059
PR
Negative 100 494 ± 352 0.061 0.839 ± 0.633 0.059
Positive 154 597 ± 384 1.034 ± 0.772
ER/PR
A:ER,PR both − or
either + 134 473 ± 316 0.005 0.837 ± 0.536 0.355
B: ER+/PR+ 129 618 ± 381 0.930 ± 0.617
Her2/neu receptor
Negative 56 444 ± 333 0.101 0.727 ± 0.518 0.023
Positive 168 531 ± 346 1.127 ± 1.184
∗P values are from Mann-Whitney or Kruskal-Wallis test. The P values <0.05 are in bold, indicating signiﬁcance; the P values >0.05, but <0.15 are in italic,
indicating weak signiﬁcance.
normaltissue(T/Nratio<1).About53%(155/293 = 52.9%)
of tumor tissues, the mtDNA content decrease to lower than
80% of that in the surrounding normal tissue counterpart,
while only around 25% (74/293) of tumor tissues have T/N
ratios>1.2.ThemtDNAcontentintumortissueandtheT/N
ratio does not correlate with the age of the patient (Table 1).
3.2. The mtDNA Content in Tumor Tissue Varies with Tumor
Size. When mtDNA content was plotted against tumor size,
itwasnoticedthatmtDNAcontentintumortissuedecreased
with increased tumor size up to 50cm3 (Figure 1). However,
when the tumor size is >50cm3, the mtDNA content in
tumor started to increase (Figure 1). The average mtDNA
content in tumors sized 30–49.9cm3 was signiﬁcantly lower
when compared to mtDNA content in smaller or larger
tumors (Figure 1 and Table 1). In contrast, the mtDNA
contentin the surrounding normaltissue remained relatively
constant regardless of tumor size (Figure 1). Similar to
mtDNA content in tumor, the T/N ratio also varied with the
tumor size (Figure 1 and Table 1).
3.3. Correlation of mtDNA Content with the Pathological
Grade and Stage of Tumors. T h em t D N Ac o n t e n t si nt u m o r
tissues and the T/N ratios were signiﬁcantly higher in grade
III tumors than in grade II tumors, P = 0.006 (Table 1 and
Figure 2).Therewerefewersgrades0andItumors(18/241 =
7.5 % ) .T h em t D N Ac o n t e n ti ng r a d e0 - It u m o r sw a sa l s o
signiﬁcantly higher when compared to grade II tumors (P =
0.019, Table 1 and Figure 2) .T h em t D N Ac o n t e n td o e sn o t
correlate with tumor stage. However, the mtDNA content in
tumors at stages 0-I or stage II is lower than that in tumors at
stage III∼IV, P = 0.073.
3.4. mtDNA Content and Expression Level of ER, PR, and
HER2. InthepresenceofER,themtDNAcontentintumors
is higher than mtDNA content in ER-negative tumors, but it
does not reach the statistical signiﬁcant level (P = 0.103).
However, the T/N ratio is signiﬁcantly lower in ER negative
tumors than in ER-positive tumors (P = 0.047) (Table 1).
Likewise, both the mtDNA content and the T/N ratio are
borderlinesigniﬁcantlylowerinthePR-negativetumorsthan4 Journal of Oncology
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Figure 1: Comparison of the mtDNA content and the T/N ratio
in tumors of diﬀerent size. (a) mtDNA content of tumor tissues
and their surrounding pathologically normal tissues, in tumors
of diﬀerent size. (b) T/N ratio of tumors with diﬀerent size. T:
mtDNA content of the tumor tissue; N: mtDNA content of the
pathologically normal tissue surrounding the tumor tissue; T/N
ratio: the ratio of mtDNA content of the tumor tissue to that of the
pathologicallynormaltissuesurroundingthetumorsfromthesame
individual; X-axis represents tumor size in cubic centimeter (totally
11 groups); the Y-axis represents mtDNA content (mtDNA/B2M
gene) and T/N ratio respectively in (a) and (b); the results from
other size groups were compared with those from the group of
tumors sized 30–49.9 cubic centimeters; the symbols of, Δ, ∗, ∗∗,
∗∗∗, ∗∗∗∗ and ∗∗∗∗∗ represent signiﬁcant P values of <0.1, <0.05,
<0.01, <0.001, <0.0001 and <0.00001, respectively.
in PR-positive tumors (P = 0.061 and 0.059, resp.) (Table 1).
Similarly, for HER2, the T/N ratio is signiﬁcantly lower in
HER2-negative tumors than in HER2-positive tumors (P =
0.023)(Table 1).ThemtDNAcontentinER-andPR-positive
(ER+/PR+) tumors is also signiﬁcantly higher than in ER/PR
both negative or either positive tumors (P = 0.005, Table 1).
3.5. Somatic mtDNA Alterations. Of the 74 tumor/normal
tissue pairs analyzed, somatic alterations were detected
in 34 tumors (34/74 = 46%); 19 had somatic alter-
ations in the non-coding D-loop region only, 15 harbored
alterations in coding region. Seven of the 15 with cod-
ing region changes also contained alterations in D-loop
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Figure 2: Comparison of the mtDNA content and the T/N ratio
in tumors of diﬀerent grade. (a) mtDNA content of tumor tissues
and their surrounding pathologically normal tissues, in tumors of
diﬀerent grade. (b) T/N ratio of tumors with diﬀerent grade. T,
mtDNA content of the tumor tissue; N: mtDNA content of the
pathologically normal tissue surrounding the tumor tissue; T/N
ratio: the ratio of mtDNA content of the tumor tissue to that of
the pathologically normal tissue surrounding the tumors from the
same individual; X-axis represents tumor histological grade; the Y-
axis represents mtDNA content (mtDNA/B2M gene) and T/N ratio
respectively, in (a) and (b); the results from tumors of grades 0 and
I and grade III were compared with those from tumors of grade II;
The symbols ∗ and ∗∗ represent signiﬁcance P value of <0.05 and
<0.01, respectively.
region. The detail of somatic mtDNA changes are listed in
Table S1 of the supplementary material available online at
doi:10.1155/2011/496189.
3.6. mDNA Content and Somatic mtDNA Alterations. As
shown in Table 2, the mtDNA content and the T/N ratio in
tumors with somatic mtDNA alterations in coding regions,
are signiﬁcantly higher than in tumors without somatic
mtDNA alterations (P<0.001) or with alterations in the D-
loop region (P<0.001). The proportion of tumors with T/N
ratio greater than 1.2 is also signiﬁcantly higher in tumors
with somatic mtDNA alterations in coding regions than in
tumors without somatic mtDNA alterations (P = 0.033)
or with alterations in the non-coding D-loop region (P =
0.001). In contrast, the mtDNA content and the T/N ratio inJournal of Oncology 5
T
a
b
l
e
2
:
S
o
m
a
t
i
c
a
l
t
e
r
a
t
i
o
n
s
a
n
d
a
l
t
e
r
a
t
i
o
n
s
o
f
m
t
D
N
A
c
o
n
t
e
n
t
.
R
e
g
i
o
n
s
w
i
t
h
s
o
m
a
t
i
c
a
l
t
e
r
a
t
i
o
n
s
A
l
t
e
r
a
t
i
o
n
o
f
m
t
D
N
A
c
o
n
t
e
n
t
m
t
D
N
A
c
o
n
t
e
n
t
i
n
t
u
m
o
r
t
i
s
s
u
e
T
/
N
r
a
t
i
o
T
/
N
r
a
t
i
o
<
0
.
8
T
/
N
r
a
t
i
o
>
1
.
2
M
e
a
n
±
S
D
P
v
a
l
u
e
∗
M
e
a
n
±
S
D
P
v
a
l
u
e
∗
n
%
O
d
d
s
9
5
%
C
I
(
L
o
w
-
H
i
g
h
)
P
v
a
l
u
e
∗
∗
n
%
O
d
d
s
9
5
%
C
I
(
l
o
w
-
H
i
g
h
)
P
v
a
l
u
e
∗
∗
A
D
-
l
o
o
p
o
n
l
y
(
n
=
1
9
)
4
9
6
±
1
8
1
<
0
.
0
0
1
Δ
0
.
6
5
±
0
.
3
5
<
0
.
0
0
1
Δ
1
1
5
7
.
9
1
.
3
8
0
.
4
6
–
4
.
1
4
0
.
5
9
1
Δ
1
5
.
3
0
.
1
5
0
.
0
2
–
1
.
2
3
0
.
0
8
1
B
C
o
d
i
n
g
w
i
t
h
/
w
i
t
h
o
u
t
D
-
l
o
o
p
(
n
=
1
5
)
7
2
4
±
3
6
9
<
0
.
0
0
1
Δ
<
0
.
0
0
1
Δ
Δ
1
.
3
5
±
0
.
7
1
<
0
.
0
0
1
Δ
<
0
.
0
0
1
Δ
Δ
4
2
6
.
7
0
.
3
6
0
.
2
6
0
.
1
–
1
.
3
4
0
.
0
6
–
1
.
1
4
0
.
1
4
1
Δ
0
.
0
9
1
Δ
Δ
9
6
0
3
.
9
5
2
7
1
.
1
4
–
1
3
.
7
3
2
.
8
1
–
2
6
0
.
0
3
3
Δ
0
.
0
0
1
Δ
Δ
C
N
o
(
n
=
4
0
)
5
6
2
±
3
1
0
1
.
2
2
±
1
.
4
1
2
0
5
0
1
1
2
7
.
5
T
/
N
r
a
t
i
o
:
t
h
e
r
a
t
i
o
o
f
m
t
D
N
A
c
o
n
t
e
n
t
i
n
t
u
m
o
r
t
i
s
s
u
e
t
o
t
h
e
m
t
D
N
A
c
o
n
t
e
n
t
i
n
s
u
r
r
o
u
n
d
i
n
g
n
o
r
m
a
l
t
i
s
s
u
e
;
S
D
:
s
t
a
n
d
a
r
d
d
e
v
i
a
t
i
o
n
;
∗
:
M
a
n
n
-
W
h
i
t
n
e
y
t
e
s
t
;
∗
∗
:
F
i
s
h
e
r
’
s
e
x
a
c
t
t
e
s
t
,
Δ
v
e
r
s
u
s
n
o
s
o
m
a
t
i
c
a
l
t
e
r
a
t
i
o
n
s
(
C
)
;
Δ
Δ
v
e
r
s
u
s
n
o
n
-
c
o
d
i
n
g
D
-
l
o
o
p
r
e
g
i
o
n
a
l
t
e
r
a
t
i
o
n
s
o
n
l
y
(
A
)
.
T
h
e
P
v
a
l
u
e
s
<
0
.
0
5
a
r
e
i
n
b
o
l
d
,
i
n
d
i
c
a
t
i
n
g
s
i
g
n
i
ﬁ
c
a
n
c
e
;
t
h
e
P
v
a
l
u
e
s
>
0
.
0
5
,
b
u
t
<
0
.
1
5
a
r
e
i
n
i
t
a
l
i
c
,
i
n
d
i
c
a
t
i
n
g
w
e
a
k
s
i
g
n
i
ﬁ
c
a
n
c
e
.6 Journal of Oncology
tumors with somatic mtDNA alterations in the non-coding
D-loop region, are signiﬁcantly lower than those in tumors
without somatic mtDNA alterations, P<0.001. Meanwhile,
the proportion of tumors with T/N ratio greater than 1.2
is lower in tumors with somatic mtDNA alterations in the
non-coding D-loop region than in tumors without somatic
mtDNA alterations (P = 0.081). These results suggest that
mtDNA alterations in coding regions, but not in the non-
coding D-loop region, tend to induce compensatory mtDNA
biogenesis. The majority of the tumors without somatic
mtDNA alterations had reduced mtDNA content compared
to surrounding normal tissue.
3.7. Linking mtDNA Content to Clinicopathological Features
and Patients’ Survival. In univariate Cox regression analysis,
patients with tumors of higher histological grade, or larger
tumor size, or in late TNM stage had a signiﬁcantly shorter
survival (higher hazard of death) rate; P values are 0.014,
0.004, and 0.011, respectively (Table 3). This is consistent
with the previous report that high histopathological grade,
large tumor size, and late TNM stage are all prognostic
factorsforsurvival[17].PatientswithlowmtDNAcontentin
tumor had signiﬁcantly lower hazard of death than patients
with median (relatively normal) level of mtDNA content in
tumor (P = 0.042). After adjusting for the factors including
tumor grade, tumor size, and patients’ age, the hazard ratio
of patients with both low and high mtDNA content in
the tumor tissue became signiﬁcantly higher compared to
patients with median level of mtDNA content in the tumor
tissue (HR = 3.39, 95% CI = 1.17–9.82, P = 0.025 for
patients with low mtDNA content; HR = 4.05, 95% CI
= 1.27–12.87, P = 0.018 for patients with high mtDNA
contentinthetumortissue)(Table 3).Thereisnocorrelation
between the hazard ratio and T/N ratio.
4. Discussion
Mitochondria play a central role in cellular energy pro-
duction. Approximately 90% of cellular energy is produced
by the electron transport chain embedded in the inner
mitochondrial membrane though the process of oxidative
phosphorylation [18–20]. Although many factors, includ-
ing the mutual interaction between mitochondrial energy
state, biogenesis, metabolite, dynamics, and degradation are
involved in the regulation of cellular and mitochondrial
energy production [21], the interplay between nuclear and
mitochondrial genes may hold the ﬁnal understanding of
the mitochondrial role in the disease processes [22]. Altered
mitochondrial function in cancer cells has been recognized
and postulated to be the fundamental cause of cancer [2, 3].
Downregulation of mitochondrial oxidative phosphoryla-
tion is a common phenotype in cancers [4]. However, only
a few reports link altered mitochondrial function directly to
deleterious mtDNA point mutations [23–25].
Altered mitochondrial function can be caused by qual-
itative or quantitative changes in nuclear or mitochon-
drial encoded genes. Primary mitochondrial DNA deple-
tion syndrome is a group of severe autosomal recessive,
heterogeneous clinical syndromes caused by mutations in
nuclear-encoded proteins responsible for mitochondrial
DNA biosynthesis or the maintenance of mitochondrial
deoxynucleotide pools [26–30]. Cancer has not been the
main clinical feature of mtDNA depletion syndrome. How-
ever, our recent study [27] revealed that infant patients
withmutationsinDGUOK (deoxyguanosinekinase)MPV17
genes had developed hepatocellular carcinoma (HCC) [26–
28, 30]. Thus, it is possible that mtDNA depletion is
associated with HCC in young age. Most patients with
congenital mtDNA depletion syndrome died at young age
(<2y e a r s )b e f o r ec a n c e rd e v e l o p e d .
R e d u c t i o no fm t D N Ai nt u m o rt i s s u e sh a v eb e e n
reported in a variety of human cancers, including HCC
[7, 31, 32], breast [6, 33], gastric [10], and other cancers
[14,34].However, contradictoryobservations havealsobeen
reported [35, 36]. Depletion of mtDNA such as rho (0)
cells showed diminished proliferation and tumorigenicity
[35,36].Althoughmitochondrial membranepotential(Ψm)
was markedly reduced, the apoptotic rate of T47D rho(0)
cells remained the same as that of their parental cells
[36]. Clinically, overall increased mtDNA content had been
reported in premalignant and malignant head and neck
lesions [5] and ovarian cancer [37]. For this reported overall
decrease of mtDNA content in tumors, there was always
increased mtDNA content in some of the samples studied
[6, 7, 10, 14, 31–34]. Most of these studies had sample size
less than 100.
In this report, we studied the mtDNA content in 302
pairs of tumor/normal breast tissue. Overall, the mtDNA
content in tumor tissues was signiﬁcantly lower than the
mtDNA content in the surrounding normal tissues. About
53% of tumor tissues have reduced mtDNA content (T/N
ratio < 0.8) compared to surrounding normal tissue, while
only about 25% tumors have higher mtDNA contents (T/N
ratio > 1.2) than their surrounding normal tissues. This
is consistent with most of the published studies [6, 7, 10,
14, 31–34] that reported that between 22.6% and 63% of
tumortissueshaddecreasedmtDNAcontent.Inaddition,we
studied mtDNA content in 20 pairs of tumor/normal tissues
eachofesophageal,liver,lung,andoralcancers(unpublished
data). The results were consistent with what was observed in
breast cancers in this study. The change, increase or decrease,
in mtDNA content in tumors apparently depends on the
stage of tumor progression, histopathological grades, size of
tumors, and the expression of estrogen and progesterone
receptors [5, 8, 33]. In contrast to the small size of the
studies performed by other researchers, the large sample size
of our study allows us to compare the mtDNA content in
tumors of diﬀerent clinico-pathological subgroups. Similar
to our results, Yamada et al. also observed a decrease in
mtDNA content with increasing tumor size in HCC [32].
The underlying mechanism for this decrease of mtDNA
content with increased tumor size is not clear. Oxygen
can initiate respiration and mitochondrial biogenesis [38].
Whereas under hypoxic condition in cancer cells, hypoxia
inducible factor (HIF) inhibits mitochondrial biogenesis
[39] or disrupts mitochondria by mitophagy [40]. When
tumor is growing in size, cells are becoming more hypoxic,Journal of Oncology 7
Table 3: Univariate and multivariate COX regression survival analysis.
Variables Group n Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
Grade 0–II 68 1.00 1.00
III 35 2.65 (1.22–5.74) 0.014 2.48 (1.12–5.51) 0.025
Size (CM3) <15 62 1.00 1.00
≥15 73 3.01 (1.42–6.37) 0.004 2.51 (0.96–6.55) 0.060
Age (Years) <50 78 1.00 1.00
≥50 70 1.76 (0.94–3.30) 0.076 3.75 (1.44–9.75) 0.007
mtDNA Content in Tumor
<400 50 2.17 (1.03–4.55) 0.042 3.39 (1.17–9.82) 0.025
400–600 55 1.00 1.00
>600 43 1.37 (0.59–3.16) 0.463 4.05 (1.27–12.87) 0.018
Stage
0-I 14 1.00
II 62 1.67 (0.38–7.36) 0.397
III-IV 18 7.10 (1.57–32.18) 0.011
The P values <0.05 are in bold, indicating signiﬁcance; the P values >0.05, but <0.10 are in italic, indicating weak signiﬁcance. HR: hazard ratio; 95% CI: 95%
conﬁdence interval.
mitochondrial biogenesis is decreased. An alternative expla-
nation for the decreased mtDNA content in tumor tissues
with increased tumor size could be that unchanged mtDNA
biosynthesis rate is unable to catch up with the accelerated
cellular proliferation in tumors. However, when the tumor
grows very large (>50cm3) and becomes invasive, mtDNA
content increases with tumor size (Figure 1), possibly
because initially during the tumor size increase and the
mtDNA content decrease, the function of the mitochondria
isincreasinglydamaged.Whenthetumorbecomesverylarge
andinvasive,themitochondrialfunctionisseverelydamaged
either due to very low mtDNA content or mutations in
the mtDNA or nuclear genes; the induction of HIF under
hypoxia condition is inhibited [41] and mtDNA biogenesis is
no longer inhibited, so the mtDNA content starts to increase.
Increased mtDNA content in the extremely large tumors
may also be a compensatory response to severely damaged
mitochondrial function [42, 43]. Interestingly, breast tumors
with increased mtDNA content have a lower sensitivity to
chemotherapy [44].
Synthesis of mitochondrial DNA is fully controlled by
nuclear encoded genes. These genes may be under the
regulation of tumor suppressor or oncogenes. For example,
the small subunit of p53-inducible ribonucleotide reductase,
RRM2B, is a heterotetrameric enzyme responsible for the
de novo synthesis of deoxyribonucleoside diphosphates that
are essential for DNA synthesis during cell cycle checkpoint
for DNA damage [45, 46]. Thus, cancer cells bearing p53
or RRM2B mutations could theoretically aﬀect mtDNA
biosynthesis, leading to mtDNA depletion. Similarly, HCC
was found in a patient with hepatocerebral form of mtDNA
depletion syndrome caused by mutations in DGUOK gene
responsible for mitochondrial salvage synthesis of deoxynu-
cleotides [47]. These results suggest a possible link between
mtDNA depletion and tumorigenesis.
Our results also showed that the mtDNA content was
signiﬁcantly higher in high grade (Grade III) breast tumors
than those in lower grade (Grade II) tumors. It is possible
that in high grade tumors HIF expression is inhibited and
mitochondrial biogenesis and mtDNA biosynthesis is no
longer inhibited [41]. Alternatively, expression of oncogenes,
growth factors, and metastatic proteins, during tumor pro-
gression, may also regulate mitochondrial biogenesis. This
is evident by a recent report [8] that shows that epithelial
tumors could be categorized to type I and type II tumors.
Mutations in KRAS and BRAF are common in low grade
t yp eIs e r o u so v a r i a nc a r c i n o m a s[ 48, 49], which have higher
mtDNA content than type II tumors that are frequently
associated with p53 mutations. P53 is involved in the
regulation of mitochondrial transcription and replication
[50]. P53 also interacts with mitochondrial polymerase
gammatoenhancemtDNAbiogenesis[51].Thus,depending
on which nuclear genes are mutated, and at what stage,
mtDNA content may vary.
The relationship between mtDNA content and the
expression of ER or PR has not been well characterized.
Some reports showed no signiﬁcant diﬀerence in mtDNA
content between ER+/PR+ and ER−/PR− breast tumors
[6, 33], however, the sample size was pretty small. With a
large sample size in the present study, our results showed
that ER+/PR+ tumors have a signiﬁcantly higher mtDNA
content compared to the tumors of ER−/PR−,E R + / P R −,o r
ER−/PR+. These results suggest that expression of ER and
PR may stimulate mitochondrial biogenesis [52].
Somatic mtDNA mutations in D-loop region, where the
origin of replication is located, may also alter the rate of
mtDNA biosynthesis [32, 33, 45]. Our data also showed
that tumors with somatic mutations in D-loop region have
signiﬁcantly decreased mtDNA content. In contrast, the ma-
jority of tumors harboring somatic alterations in the coding
regions for the rRNA, tRNA, or mRNA have increased
mtDNA content. Since alterations in the coding regions are
more likely to result in functional change, the increase in
mtDNA content may reﬂect a mechanism to compensate
the reduction in mitochondrial function [43]. Studies of
mtDNA content in HCC [32] and breast cancer [33] also8 Journal of Oncology
demonstrated that mutations in D-loop does not correlate
with mtDNA copy number in tumor [32, 33]. However,
mutation analysis in these studies did not include the coding
regions.
Advanced age, higher histological grade, larger tumor
size, and later TNM stage are all prognostic factors for sur-
vival of cancer patients [17]. In this study, univariate and/or
multivariate analysis revealed that advanced age, higher
histological grade, larger tumor size, and later TNM stage all
have a higher hazard of death than their lower counterparts.
The results also showed that tumors with both very low
and very high mtDNA content have higher hazard of death.
Since the majority of the tumors with lower mtDNA content
have larger tumor size, and high grade tumors have relatively
higher mtDNA content, and invasive nature, these observa-
tions may simply reﬂect the link of hazard of death with the
tumor size and tumor grade, respectively.
5. Conclusion
OurresultsindicatethatthemtDNAcontentintumortissues
changeswithtumorsize,grade,andER/PRstatus.Signiﬁcant
deviation from the medium range is associated with poor
survival. Low levels of mtDNA content suggest rapid tumor
growth, while high levels of mtDNA content may indicate
that tumors become invasive.
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